The Future of Heart Valve Treatment: Proven Therapies and Patient Impact

Published: 06 February 2025
Likes: 4
Average (rating)
No ratings
Your rating

Overview

Join us for an exclusive webinar, part of the Beyond the Heartbeat series, that delves into the latest advancements in mitral and tricuspid regurgitation treatment. Our expert panel will equip you with details related to groundbreaking clinical trial data and practical insights to enhance your professional practice.

Learning Objectives:

  • Explore Proven Therapies: Discover recent clinical data from the CLASP IIDTM and TRISCEND IITM trials, showcasing the benefits of minimally invasive therapies.

  • Address Critical Gaps: Recognize the significance of under-referral of mitral/tricuspid regurgitation patients, and their impact on patient outcomes and quality of life.

  • Implement Best Practices: Learn effective strategies for patient identification and referral to ensure timely and appropriate treatment.

Don’t miss this opportunity to stay at the forefront of heart valve treatment and improve patient outcomes. Register now to secure your spot!

Learning Objectives

  • Explore Proven Therapies: Discover recent clinical data from the CLASP IID™ and TRISCEND II™ trials, showcasing the benefits of minimally invasive therapies
  • Address Critical Gaps: Recognize the significance of underdiagnosis, under referral, and undertreatment of mitral/tricuspid regurgitation patients, and their impact on patient outcomes and quality of life
  • Implement Best Practices: Learn effective strategies for patient identification and referral to ensure timely and appropriate treatment

Target Audience

  • Referring Cardiologists

Agenda

Introduction

Brian O'Neill, MD

CLASP IID™ and TRISCEND II™ Data Presentation

Brian O'Neill, MD

Roundtable: Challenges in Management and Referral of MR/TR Patients

Bryan Zweig, MD, Ryan Gindi, MD and Brian O'Neill, MD

Roundtable: Practical Solutions to Implement Today

Bryan Zweig, MD, Ryan Gindi, MD and Brian O'Neill, MD

Summary and Conclusion

Brian O'Neill, MD

This webinar is supported by Edwards Lifesciences
Edwards Lifesciences